MARKET

BNTC

BNTC

Benitec Biopharm
NASDAQ
13.84
+1.22
+9.67%
After Hours: 13.83 -0.01 -0.07% 19:52 07/09 EDT
OPEN
12.98
PREV CLOSE
12.62
HIGH
13.88
LOW
12.64
VOLUME
113.17K
TURNOVER
--
52 WEEK HIGH
17.15
52 WEEK LOW
7.05
MARKET CAP
363.31M
P/E (TTM)
-8.3813
1D
5D
1M
3M
1Y
5Y
1D
Benitec Biopharma Advances BB-301 Clinical Study
TipRanks · 10h ago
BENITEC BIOPHARMA INC - ENROLLMENT OF COHORT 2 EXPECTED TO BEGIN IN Q4 2025 - SEC FILING
Reuters · 10h ago
Benitec Biopharma Inc. Advances BB-301 Clinical Study with Positive Safety Review, Set to Begin Enrollment for Cohort 2 in Q4 2025
Reuters · 11h ago
Benitec Biopharma Receives Green Light To Advance BB-301 Trial After Safety Review; Cohort 2 Enrollment Set For Q4 2025
Benzinga · 19h ago
Benitec reports DSMB recommendation to continue enrollment of Phase 1b/2a study
TipRanks · 19h ago
BENITEC BIOPHARMA PROVIDES OPERATIONAL UPDATES
Reuters · 19h ago
BENITEC BIOPHARMA INC <BNTC.O>: TD COWEN INITIATES COVERAGE WITH BUY RATING
Reuters · 2d ago
Weekly Report: what happened at BNTC last week (0630-0704)?
Weekly Report · 2d ago
More
About BNTC
Benitec Biopharma Inc is a clinical-stage biotechnology company. The Company is focused on the advancement of novel genetic medicines. Its proprietary Silence and Replace deoxyribonucleic acid (DNA) -directed ribonucleic acid (RNA) interference platform combines RNA interference, or RNAi, with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The Company is developing Silence and Replace-based therapeutics (BB-301) for chronic and life-threatening human conditions including Oculopharyngeal Muscular Dystrophy (OPMD). BB-301 is an adeno-associated viral vector (AAV)-based gene therapy designed to silence the expression of disease-causing genes (to slow, or halt, the underlying mechanism of disease progression) and to simultaneously replace the mutant genes with normal, wildtype genes.

Webull offers Benitec Biopharma Inc stock information, including NASDAQ: BNTC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BNTC stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BNTC stock methods without spending real money on the virtual paper trading platform.